Antibody Drug Conjugates (ADCS) Market to Reach Valuation of USD 13.17 Billion by 2028 - Increasing Number of Clinical Trials for New Cancer Therapeutics Drive the Market

Vantage Market Research

Feb 09, 2022

In terms of revenue, the Global Antibody Drug Conjugates (ADCS) Market is expected to reach USD 13.17 Billion by 2028, growing at a Compound Annual Growth Rate (CAGR) of 18.80% from 2022 to 2028. Factors such as, unhealthy lifestyle of people, increasing adoption of tobacco & alcohol in developing & under-developing economies and rising prevalence of cancer across globe are majorly increasing the risk of cancer. Thus, it increases the demand for quality care cancer treatment and further drive the Antibody Drug Conjugates (ADCS) Market growth.

Key Findings:

  • HER2 antibodies sub-segment of mechanism of action segment accounted potential growth for Antibody Drug Conjugates (ADCS) Market in 2021. This is mainly attributed to the availability of trastuzumab and other specific HER2 antigen targeted therapies in the market.
  • Breast cancer application segment held maximum share for Antibody Drug Conjugates (ADCS) Market in 2021. Growing R&D for breast cancer treatment is one of the key factors for bolstering the segmental growth of Antibody Drug Conjugates (ADCS) Market.
  • North America is the largest regional segment in 2021. Presence of advanced technology for cancer treatment in countries such as United States, Canada, and Mexico is one of the key factors for influencing the growth of Antibody Drug Conjugates (ADCS) Market in this region.

Some of key players in Antibody Drug Conjugates (ADCS) Market include - Takeda Pharmaceutical Company Ltd. (Japan), F. Hoffmann-La Roche Ltd. (US), Pfizer Inc. (US), AstraZeneca (Sweden), Gilead Sciences Inc. (US), Astellas Pharma (Japan), Seagen Inc. (US), Daiichi Sankyo Company Ltd. (Japan), GlaxoSmithKline PLC (UK), ADC Therapeutics (Switzerland).

Increasing government investment for Research and Development (R&D) activities, growing prevalence of different types of cancer across globe and increasing geriatric population are some of the factors that flourishing the growth of Antibody Drug Conjugates (ADCS) Market in upcoming years. The use of antibody drug conjugates is to increase the cell killing potential of monoclonal antibodies. It is derived from cytotoxic chemotherapy drug, antibody drug, and a linker. All these factors are responsible for experiencing the high demand for Antibody Drug Conjugates (ADCS) Market in coming years. In addition, emergence of advanced antibody therapies, increasing emphasis of pharmaceutical companies on new drug discovery, and increasing number of clinical trials for new cancer therapeutics are some other factors that bolster the growth of Antibody Drug Conjugates (ADCS) Market during the projected years.

The COVID-19 outbreak has affected various industries worldwide. The Antibody Drug Conjugates (ADCS) Market has no exception. Governments across the world took severe actions like border seals, lockdown, and implementing strict social distancing measures, in order to stop swift spread of COVID-19. Owing to this, the activities related to healthcare services & hospitals were decreased. Thus, it manifested the strong effect on Antibody Drug Conjugates (ADCS) Market. In addition, small & medium-scale companies are the backbone of technology providers and are witnessing a steep drop in revenue since the emergence of the pandemic in 2020. Hence, market players faced numerous challenges as disruptions in the supply chain were observed.

Antibody Drug Conjugates (ADCS) Market by Application (Breast Cancer, Urothelial Cancer & Bladder Cancer, Other Cancer, Blood Cancer), by Technology (Cleavable Linker, Non-Cleavable Linker, Linkerless), by Region (North America, Europe, Asia Pacific, Latin America) - Global Industry Assessment (2016 - 2021) & Forecast (2022 - 2028)